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Abstract
Clostridium perfringens is the causative agent of clostridial myonecrosis or gas gangrene and produces many different
extracellular toxins and enzymes, including the cysteine protease a-clostripain. Mutation of the a-clostripain structural gene,
ccp, alters the turnover of secreted extracellular proteins in C. perfringens, but the role of a-clostripain in disease
pathogenesis is not known. We insertionally inactivated the ccp gene C. perfringens strain 13 using TargeTron technology,
constructing a strain that was no longer proteolytic on skim milk agar. Quantitative protease assays confirmed the absence
of extracellular protease activity, which was restored by complementation with the wild-type ccp gene. The role of a-
clostripain in virulence was assessed by analysing the isogenic wild-type, mutant and complemented strains in a mouse
myonecrosis model. The results showed that although a-clostripain was the major extracellular protease, mutation of the
ccp gene did not alter either the progression or the development of disease. These results do not rule out the possibility
that this extracellular enzyme may still have a role in the early stages of the disease process.
Citation: Chakravorty A, Awad MM, Hiscox TJ, Cheung JK, Carter GP, et al. (2011) The Cysteine Protease a-Clostripain is Not Essential for the Pathogenesis of
Clostridium perfringens-Mediated Myonecrosis. PLoS ONE 6(7): e22762. doi:10.1371/journal.pone.0022762
Editor: Mahfuzur R. Sarker, Oregon State University, United States of America
Received May 12, 2011; Accepted June 28, 2011; Published July 29, 2011
Copyright:  2011 Chakravorty et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This research was supported by a grant from the Australian National Health and Medical Research Council. The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: julian.rood@monash.edu
. These authors contributed equally to this work.
Introduction
Clostridium perfringens type A is a Gram positive, spore forming
anaerobic bacterium and is the causative agent of several
human diseases, including gas gangrene or clostridial myone-
crosis [1–5]. This syndrome is characterised by rapid tissue
necrosis, a paucity of polymorphonucleocytes (PMNs) in the
infected tissues and vascular leukostasis [1,4,6,7]. C. perfringens
type A produces two major extracellular toxins, a-toxin, which
is essential for disease [1], and perfringolysin O, which has been
shown to function synergistically with a-toxin to mediate disease
progression [6,7].
The extracellular cysteine protease a-clostripain was first
discovered in Clostridium histolyticum [8–10] and a homologue was
later identified in C. perfringens [11–14]. Both the C. perfringens and
C. histolyticum a-clostripain proteins exist as heterodimeric
polypeptides, consisting of a heavy chain and a light chain, which
are held together by strong, non-covalent forces [8,9,15]. They are
encoded by a single gene that contains a region encoding a
nonapeptide linker [15], the polypeptide precursor is cleaved after
secretion. Functionally, a-clostripains are arginine-specific endo-
peptidases that require calcium and reducing conditions for
optimal in vitro activity [12,13,16]. They are classified as members
of the C11 peptidase superfamily, which also includes gingipains
and legumains [12], and are grouped based on their structural and
functional similarity rather than their sequence similarity.
Other members of the C11 peptidase family include the
gingipains HrgpA and RgpB from Porphyromonas gingivalis. These
cysteine proteases play key roles during the infectious process [17–
20]. They cleave important components of the innate immune
system, thereby activating receptors that allow platelet aggregation
[20], and cleave receptors on oral epithelial cells [19]. They also
inactivate TNF-a and facilitate immune evasion [18] as well as
disrupting the host cytokine response, inactivating IL-6 [17,21].
Similarly, the cysteine protease SpeB from Streptococcus pyogenes has
been shown to be important for disease and can inhibit
immunoglobulin-mediated opsonisation and phagocytosis [22,23]
and can cleave and degrade human fibronection, vitronectin, and
the C3 component of the complement system [24].
The role of C. perfringens a-clostripain in disease is not known.
Previous workers [25] have made a single crossover mutation in
the C. perfringens strain 13 a-clostripain gene, which has been
designated as ccp [14] or clp [25]. Their results provided evidence
that a-clostripain was required for the processing of secreted
proteins since disruption of the ccp gene led to an increase in the
levels of extracellular proteins [25]. In addition, a-clostripain
production is positively and directly regulated by the VirSR two-
component signal transduction system [14,26], which also
regulates perfringolysin O, a-toxin and collagenase production
in C. perfringens. Recent in vivo studies have shown that when
injected into the dorsal skin of mice, purified a-clostripain
increases intravascular permeability in a dose-dependent manner
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swelling observed in clostridial myonecrosis [16]. In summary, it
has been postulated that a-clostripain has the potential to affect
the levels of active extracellular toxins and enzymes in the region
surrounding C. perfringens cells and may therefore affect disease
progression and virulence [13].
The objective of this study was to determine if a-clostripain was
essential for disease. Accordingly, the ccp gene was insertionally
inactivated, the mutation complemented with the wild-type ccp
gene and the resultant panel of isogenic strains analysed for total
protease activity, extracellular toxin production and virulence in
the mouse myonecrosis model. The results showed that although
a-clostripain is the major protease produced by C. perfringens it is
not essential for disease.
Results
a-clostripain is the major protease produced by
C. perfringens
To assess the role of a-clostripain in the pathogenesis of C.
perfringens-mediated myonecrosis, the a-clostripain structural gene,
ccp, in the strain 13 derivative, JIR325, was insertionally
inactivated using TargeTron technology [27]. Primers were
designed using the Sigma Aldrich website (http://www.sigma-
genosys.com/targetron/) to allow for re-targeting of the 1.8 kb
group II intron, using the vector pJIR3562 [27], to a site 210
nucleotides downstream of the ccp start codon, thereby disrupting
the gene. Potential mutants were selected based on the presence of
an active erm(B) erythromycin resistance cassette located within the
integrated group II intron and then screened for the absence of
zones of precipitation on skim milk agar. Two independent ccp
mutants were isolated and their genotype confirmed by Southern
hybridisation. The results showed that a ccp-specific probe
hybridised with a 3.9 kb HindIII fragment in DNA from the
wild-type strain and a 5.7 kb fragment in the mutants, as expected
since these derivatives contained a 1.8 kb insertion within the ccp
gene (data not shown). The 5.7 kb fragment also hybridised with
an erm(B)-specific probe. The plasmid pJIR3680, which contains
the full-length ccp gene with its natural promoter, was used to
complement the ccp mutation.
Quantitative protease assays showed that the ccp mutant
carrying the vector plasmid pJIR750 had no detectible protease
activity when compared to the wild-type strain (Fig. 1). Protease
activity was restored to wild-type levels when pJIR3680 was used
to complement the ccp mutation. These data indicate that a-
clostripain is the major extracellular protease produced by
derivatives of C. perfringens strain 13.
Disruption of ccp does not affect a-toxin and
perfringolysin O production or hemoglobin degradation
Previous studies have shown that a-clostripain is involved in the
processing and degradation of extracellular proteins produced by
C. perfringens [25]. Therefore, we used quantitative toxin assays to
determine if the ccp mutation altered the levels of the two major
extracellular toxins, a-toxin and perfringolysin O. No significant
differences in a-toxin (Fig. 2A) or perfringolysin O activity (Fig. 2B)
were observed in supernatants derived from exponential growth
phase cultures of wild-type strain, the ccp mutant carrying the
vector plasmid or the complemented mutant. These results
strongly suggest that a-clostripain is not involved in the processing
or degradation of either of these two major toxins.
Acquisition of iron from iron-rich proteins like hemoglobin is
one of the major factors that influence the progression and
establishment of many bacterial infections [28]. The cysteine
Figure 1. The ccp mutant has no detectable protease activity.
Culture supernatants (n=4) isolated at 3.5 h from the wild-type strain
JIR325 (WT), a ccp mutant carrying the vector plasmid pJIR750 M(v)
(JIR12503), and the ccp mutant carrying the ccp
+ complementation
plasmid pJIR3680, M(ccp
+) (JIR12501) were assayed for protease activity
as previously described [26] and results expressed as the rate of azo-dye
release/minute/mg protein. Error bars indicate S.E.M (*** p,0.0001)
using a two-tailed unpaired student’s t-test comparing the WT and
M(v).
doi:10.1371/journal.pone.0022762.g001
Figure 2. a-toxin and perfringolysin O activity in culture
supernatants of isogenic strains. Mid-exponential phase culture
supernatants from the wild-type strain (WT), a ccp mutant carrying the
vector plasmid pJIR750, M(v), and the ccp mutant carrying the ccp
+
complementation plasmid pJIR3680, M(ccp
+), were either concentrated
5-fold or used undiluted to assay for a-toxin (A) or perfringolysin O
activity (B), respectively (n=3). Error bars represent S.E.M.
doi:10.1371/journal.pone.0022762.g002
a-Clostripain is Not Essential for Myonecrosis
PLoS ONE | www.plosone.org 2 July 2011 | Volume 6 | Issue 7 | e22762protease falcipain-3 from Plasmodium falciparum, for example, has
been shown to degrade human hemoglobin, which is a key
mechanism of nutrient acquisition [29,30]. More recently, the
extracellular protease LepA from Pseudomonas aeruginosa also was
shown to degrade hemoglobin, thereby enabling the bacterium to
acquire peptides and heme, and was found to contribute to the
growth and virulence of this bacterium, cooperatively with PlcH, a
haemolytic phospholipase C [31]. Therefore, we decided to assess
the ability of a-clostripain to degrade human hemoglobin, which
may be an important nutrient source for C. perfringens cells in
infected host tissues. We developed a heme release assay to
measure the cleavage and release of human hemoglobin. Briefly,
human hemoglobin was mixed in equal quantities with culture
supernatants from the isogenic wild-type, ccp mutant and
complemented strains. Incubation with trypsin, which was used
as a positive control, showed that heme was released under these
physiological conditions. By contrast, no difference in the level of
hemoglobin degradation was observed between the wild-type, the
ccp mutant and the complemented strains (Fig. 3), suggesting that
a-clostripain is not be involved in hemoglobin degradation under
these conditions.
a-clostripain does not affect the host cell cytotoxicity of
culture supernatants
C. histolyticum a-clostripain has been shown to induce cell death
and cytopathic effects on tissue culture cells, even at low dilutions
[32]. Furthermore, purified HrgpA and RgpB, live P. gingivalis
cells, and filtered culture supernatants were capable of inducing
apoptosis in primary human gingivial epithelial cells unlike heat-
killed P. gingivalis cells [33]. Since previous work suggested that
mutation of the a-clostripain gene had the potential to alter the
levels of secreted C. perfringens proteins [13,34], and therefore to
potentially affect their interaction with host cells, we decided to
determine the effect of isogenic culture supernatants on host cell
survival. Differentiated DC2C12 mouse muscle cells were
incubated with filter-sterilised culture supernatants from the
wild-type, ccp mutant and complemented strains for 24 h and
cellular cytotoxicity determined using an MTT (3-(4,5-di-
methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) cell viability
assay (Fig. 4). Treatment with 1% Triton-X100 (v/v) was used a
positive control. The results showed that there was no statistically
significant difference in DC2C12 cell cytotoxicity upon treatment
with these culture supernatants.
a-clostripain is not essential for virulence in the mouse
myonecrosis model
Finally, the virulence of the isogenic ccp strains was assessed in
our mouse myonecrosis model. Balb/c mice were injected
intramuscularly with live, washed bacteria (10
9 cfu) [35,36].
Disease progression was analysed over 12 h and scored for
characteristic disease pathology, including blackening of the
footpad and the thigh, swelling of the footpad and the thigh and
limping, as before [35,36]. The results showed that mice injected
with the ccp mutant succumbed to disease at the same rate as those
infected with the wild-type or complemented strains (Fig. 5A). A
wild-type strain containing the ccp
+ complementation vector was
also constructed to assess its in vivo effects. Virulence testing
revealed that although it appeared that disease onset was delayed
in this strain, the Kaplan-Meier survival curve was not statistically
different from wild type (p.0.05, Mantel-Cox test) (Fig. 5A). No
differences were seen in the other disease parameters, including
blackening of the thigh, footpad or limping, in all of the tested
strains (data not shown).
Histopathological analysis of muscle tissues from mice infected
with the isogenic panel of strains showed that all of these strains
displayed the same pathological characteristics associated with
normal C. perfringens disease [7], including vascular leukostasis and
necrosis of the infected muscle tissues (Fig. 5B). Taken together,
the results show that mutation of the a-clostripain gene does not
affect the progression or development of clostridial myonecrosis in
the mouse model.
Discussion
The ability of bacterial cells to survive within the host is
dependent upon numerous interrelated factors, including the
ability of the organism to both evade the host immune response
Figure 3. Hydrolysis of hemoglobin. Culture supernatants from
mid-exponential phase cultures of the isogenic strains described in
Fig. 1 were used to assay for hemoglobin (Hb) hydrolysis. Culture
supernatants (n=4) were mixed with equal volumes of human
hemoglobin (1 mg/ml) and incubated for 24 h. Trypsin (0.5%) was
used as a positive control. Hemoglobin was precipitated using 3% TCA
and the absorbance of the supernatants analysed at 410 nm. The
results are shown relative to the amount of hemoglobin hydrolysed by
trypsin after 24 h. Error bars indicate S.E.M.
doi:10.1371/journal.pone.0022762.g003
Figure 4. Cytotoxicity of isogenic strains. Differentiated C2C12
cells were stimulated for 24 h at 37uCi n5 %C O 2 with filtered mid-
exponential phase culture supernatants (n=3) from the isogenic strains
described in Fig. 1. Cell viability then was assessed using an MTT assay.
Culture medium was used as negative control and 1% Triton-X100 (v/v)
was used a positive control. Error bars represent S.E.M.
doi:10.1371/journal.pone.0022762.g004
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previously shown that when purified a-clostripain from C.
perfringens was injected intradermally into mice there was an
increase in vascular permeability [16], thereby implying that a-
clostripain may play a role in the pathogenesis of clostridial
myonecrosis. This study used only purified a-clostripain and did
not consider the concentration of a-clostripain within an infected
lesion or its potential interactions with other bacterial and host
factors. These findings were in contrast to previous studies, which
have shown that an important characteristic of clostridial
myonecrosis is an absence of vascular permeability due to the
formation of platelet-leucocyte and platelet-platelet aggregates
within the vasculature and the up-regulation of adhesion
molecules on endothelial cells, leading to an occlusion of blood
flow into infected regions. [4,37–40]. Studies using an in vivo
microvascular perfusion model also have shown that treatment of
mouse cremaster muscle tissue with culture supernatants from
wild-type C. perfringens strains led to a decreased functional
capillary density [40], which was reversed when cells were pre-
treated with anti-Gr-1, a granulocyte-specific antibody, and anti-
platelet serum [40]. These data confirmed the importance of
neutrophil-platelet aggregates in blocking vascular perfusion
during C. perfringens infection.
Using a mouse myonecrosis infection model, we have now
shown that a-clostripain is not essential for C. perfringens-mediated
disease. Mice infected with an a-clostripain mutant did not show
any alteration in disease progression or in the development of
vascular leukostasis, a hallmark of C. perfringens infection (Fig. 5).
Mutation of the ccp gene also had no affect on bacterial growth or
on the extracellular level of the two major toxins, a-toxin and
perfringolysin O (Fig. 2), which are implicated in clostridial
myonecrosis [1,7]. In agreement with previous studies [41] our
results provide good evidence that a-clostripain is the major
protease produced by C. perfringens strain 13 (Fig. 1). Other
bacterial cysteine proteases, which unlike a-clostripain have been
shown to be essential for virulence, also are involved in influencing
the levels of other virulence factors, many of which have non-
redundant functions. For example, mutation of both P. gingivalis
Figure 5. Kaplan-Meier survival curve and histopathology of infected mice. (A) Kaplan-Meier survival curve. Female Balb/c mice were
inoculated into the right hind thigh muscle with the strains indicated (n=15). Mice were then observed and scored for signs of disease over 12 h.
Legend: N Wild-type (WT), %M(v), mM(ccp
+), . Wild-type (ccp
+). (p.0.05 using log-rank Mantel-Cox test comparing wild type with mutant and
complemented strains) (B) Histopathological analysis (hemotoxylin and eosin stain) of muscle tissue isolated from mice infected with the strains
indicated. Tissues showed the development of the characteristic signs of disease. M-muscle tissue, Nr M- necrotic muscle, Lk Bv- leukostatic blood
vessel, Cp- C. perfringens.
doi:10.1371/journal.pone.0022762.g005
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affects the growth and expression of cell surface structures such as
fimbriae and vesicles, both of which are thought to assist in
colonization and evasion of the immune response [42–44].
Like a-clostripain other potential C. perfringens-encoded spread-
ing factors, such as collagenase and two different sialidases, are not
to be essential for disease in the mouse myonecrosis model [3,45].
These enzymes may still have a role during infection. The
breakdown of host tissues is important for the release of nutrients
such as amino acids, sugars and essential minerals such as
sequestered iron, which are required for the growth of C. perfringens
cells in the lesion. We previously postulated that the sialidases
secreted by C. perfringens may still serve such a function even
though they are not essential for virulence [45]. Accordingly, we
tested the ability of a-clostripain to hydrolyse human hemoglobin
since other bacterial proteases can catalyze the release of heme
from hemoglobin. Although some hemoglobin degradation was
observed, there was no significant difference between the wild-type
strain and the ccp mutant, suggesting that a-clostripain does not
play a major role in hemoglobin hydrolysis.
The clostridial mouse myonecrosis model used in this study, and
many other studies [1,3,7,45], is the only animal model currently
available that allows the consistent reproduction of virulent
disease. However, since the model involves injection of anaerobic
bacteria into healthy oxygenated tissue, an infectious dose of 109
cells is required to establish reproducible disease. This process may
mask any role that extracellular enzymes such as a-clostripain,
sialidase or collagenase may have during the early stages of the
disease process. Therefore, we cannot rule out the possibility that
a-clostripain has a role in disease pathogenesis in a natural C.
perfringens infection, where a traumatic injury usually leads to the
establishment of ischemic conditions, enabling the proliferation of
small numbers of contaminating cells in the muscle tissues leading
to a major infection and fulminant gas gangrene.
Materials and Methods
Ethics Statement
Animal experiments were approved by the Monash University
School of Biomedical Sciences B (SOBSB) Animal Ethics
Committee (Approval number: SOBSB/M/2009/16) and were
conducted in accordance with Victorian State Government
regulations. All efforts were made to ameliorate any unnecessary
suffering of animals.
Bacterial strains and growth conditions
AllC. perfringens strains were derivatives of JIR325, a rifampicin and
nalidixic acid resistant derivative of strain 13 [46]. C. perfringens strains
were grown in tryptone-peptone-yeast extract glucose (TPYG) broth
supplemented with 0.375% glucose (v/v) and 0.1% sodium
thioglycolate (w/v) [47], fluid thioglycolate broth (FTG) (Difco), or
nutrient agar (2.5% Nutrient Broth (Oxoid), 0.3% yeast extract
(Oxoid), 0.1% sodium thioglycolate, 1.5% agar (Oxoid)), supple-
mented when necessary with 10 mg/ml rifampicin and 10 mg/ml
nalidixic acid for wild-type C. perfringens strains, 10 mg/ml erythro-
mycin for a-clostripain mutants or 30 mg/ml chloramphenicol for
complemented strains. Skim milk agar was made by adding 2% skim
milk powder to nutrient agar. Broth cultures were boiled for 5–
10 min prior to inoculation to render them anaerobic and agar
cultures were grown at 37uC in 10% (v/v) H2, 10% (v/v) CO2 in N2.
Molecular and genetic techniques
C. perfringens genomic [48] and plasmid DNA [49], and E. coli
plasmid DNA [50,51] were isolated as previously described.
Plasmid DNA was introduced into C. perfringens by electroporation
at 1.8 kV, 25 mF and 200 V [52]. TargeTron technology was used
to mutate the a-clostripain gene as previously described [27], using
a retargeted derivative of pJIR3562 [27]. Target sites were chosen
based on the best score provided on the Sigma Aldrich website
(http://www.sigma-genosys.com/targetron/) and primers were
designed to allow retargeting of the group II intron between
nucleotides 210 and 211 on the sense strand, at the start of the ccp
gene. C. perfringens transformants were selected on erythromycin-
containing media and were screened for the absence of proteolytic
activity on skim milk agar as well as for thiamphenicol sensitivity.
The resultant a-clostripain mutant was designated as JIR12337
and, when transformed with the plasmid vector pJIR750, as
JIR12503.
Complementation of the ccp gene
The wild-type ccp gene, including 200 base pairs upstream of the
start site to incorporate its putative promoter, were subcloned into
pCR-Blunt II TOPO (Invitrogen) to construct pJIR3679. This
plasmid and the E. coli - C. perfringens shuttle plasmid pJIR750 [53],
which carries the catP chloramphenicol resistance gene, were then
digested with BamHI (Roche) and the digested fragments mixed
and ligated with high concentration T4 DNA ligase (Roche). The
ligated mixture then was used to transform chemically competent
E. coli DH5a cells [51] and recombinants selected based on their
chloramphenicol resistance and proteolytic activity on skim milk
agar. The complementation plasmid, pJIR3680, was confirmed by
restriction analysis and sequencing and used to transform the C.
perfringens ccp mutant JIR12337 to chloramphenicol resistance [52].
Colonies were selected on skim milk nutrient agar supplemented
with 30 mg/ml chloramphenicol and screened for the restoration
of zones of proteolysis. The complemented strain was designated
as JIR12501. A wild-type strain containing the ccp complementa-
tion vector was also constructed by electroporation of JIR325 with
pJIR3680 and was designated as JIR12539.
Toxin and enzyme assays
Relevant strains were grown to mid-exponential phase (3.5 h) in
100 ml of TPYG broth; the strains all grew at the same rate. Cells
were removed by centrifugation at 8,500 g for 10 min at room
temperature. a-toxin assays were performed as previously
described, with activity presented as units/mg total protein [54]
and total protein determined using a BCA assay kit (Pierce).
Perfringolysin O activity was determined using a doubling-dilution
assay as previously described [27,55] with the addition of 5 mM
dithiothreitol (DTT) (Roche). The haemolytic titre was expressed
as the highest dilution that caused at least 80% haemolysis.
Protease assays were performed as previously described [26].
Briefly, culture supernatants were mixed with 5 mg/ml azocasein
(Sigma Aldrich) dissolved in 25 mM Tris-HCl buffer, pH 7.5,
supplemented with 5 mM DTT and incubated for 2 h at 37uC
with gentle rotation. The proteins were then precipitated from
solution with the addition of 3% (w/v) TCA and azocasein
hydrolysis determined by reading the absorbance of the superna-
tants at 570 nm. Protease activity was defined as the rate of azo-
dye release/per minute/mg of protein.
Hemoglobin degradation assay
Culture supernatants were mixed in equal quantities with
1 mg/ml human hemoglobin (Sigma Aldrich) in 25 mM Tris-HCl
buffer (pH 7.5), supplemented with 5 mM DTT and incubated for
24 h at 37uC. Trypsin (0.5%) (Invitrogen) was used a positive
control and medium only was used as a negative control. After
incubation, the mixtures were precipitated with 3% (w/v)
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measuring the absorbance of the supernatants at 410 nm.
Cell cytotoxicity assays
The mouse muscle cell line C2C12, was maintained in
Dulbecco’s Modified Eagles Medium (DMEM) (Invitrogen)
supplemented with 10 mM L-glutamine and 10% (v/v) heat
inactivated foetal bovine serum (FBS) (Sigma Aldrich). To obtain
differentiated C2C12 cells (DC2C12 cells) for subsequent
experiments, C2C12 cells (ATCC) were allowed to grow to 80
to 90% confluence and then aliquoted into 96 well microtitre
plates at 2610
4 cells well (2610
5 cells/mL) in DMEM with 2%
FBS and incubated for a further five days. The differentiated cell
monolayers then were stimulated with filter sterilised (0.4 mm)
culture supernatants from 3.5 h C. perfringens cultures for 24 h at
37uC in 5% CO2. Culture medium was used as a no stimulation
control and treatment with 1% (v/v) Triton-X100 was used as a
total cell lysis control. Cellular cytotoxicity was measured using an
MTT assay (Biocore) as per the manufacturer’s instructions.
Percentage cell death was calculated after subtracting the
absorbance from cells stimulated with medium only from the
absorbance of treated cells.
Virulence studies
Virulence trials were conducted as described previously [6,7].
Briefly, C. perfringens cultures were grown for 6 h in FTG broth and
then subcultured onto nutrient agar with appropriate antibiotic
selection. After overnight growth the cells were removed into
Dulbecco’s phosphate buffered saline (DPBS), washed in DPBS
and resuspended in three times the cell pellet volume in DPBS.
Female Balb/c mice were injected into the right hind thigh muscle
with 50 ml of this suspension (approximately 10
9 cfu) and
monitored every 30 min for 12 h for the characteristic signs of
disease pathology: blackening of the thigh and footpad, swelling of
the thigh and footpad and limping [6,7,56]. Mice were euthanised
when they developed significant disease pathology. Viable counts
of each C. perfringens stain were performed both pre- and post-
infection. Histopathology was performed on infected thigh tissue
collected from mice immediately following euthanasia and stored
in 10% phosphate buffered formalin. Tissues were sliced into
5 mm sections and stained with haematoxylin and eosin by
Monash University Histology Services. Stained sections were
analysed using an Olympus BX51 microscope with a DP70
camera.
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